Conclusions

Chapter

Abstract

  • © Springer International Publishing Switzerland 2016. The first-generation 5-HT3 receptor antagonists (dolasetron, granisetron, ondansetron, tropisetron, ramosetron, and azasetron) have significant and similar efficacy in the prevention of acute CINV for patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). These agents do not appear to have significant efficacy in the prevention of delayed CINV, and these agents compete primarily on an economic basis.
  • Digital Object Identifier (doi)

    International Standard Book Number (isbn) 13

  • 9783319270142
  • Start Page

  • 177
  • End Page

  • 178